MedPath

Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia

Not Applicable
Conditions
Refractory Schizophrenia
Registration Number
NCT01879956
Lead Sponsor
University of Sao Paulo
Brief Summary

Primary Objective:

Efficacy of Occupational Therapy (OT) based Occupational Goal Intervention (OGI) in improving executive functions in patients with refractory schizophrenia as measured by the BADS.

Secondary Objectives: improvement of functional aspects,basic and instrumental activities of daily living,negative symptoms and cognitive functions improvement

Hypothesis: OT is more effective than control group to improve executive functions in patients with refractory schizophrenia.

Detailed Description

A single-center, randomized, single blind, controlled study, lasting one year, including the follow-up.

The study is conducted in two groups:the experimental group is based on the OGI method (N=30 patients) and the control group receives craft activities (N = 30 patients).

Psychiatric, neuropsychological and functional aspects are assessed at the beginning, after 30 sessions and 6 months after the intervention. The scale PANSS (Positive and Negative Syndrome Scale) is used for monitoring psychopathological symptoms during the study.

Scales BADS, DAFS-R, ILSS-BR respectively assess executive functions, functionality and basic and instrumental activities of daily living. The neuropsychological evaluation includes a battery to measure attention, executive functions, memory and estimated intellectual efficiency.

Statistical analysis to be used: ANOVA (Analysis of Variance)for repeated measures; data are also calculated to messure clinical efficacy, effect size and needed number to treat.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Pacients with diagnosis of schizophrenia for DMS IV-R.

  • Pacients that signed the consent in writing and receive explanations about the nature of the study.

  • Patients who carefully counted another responsible person to provide reliable support to the patient and ensure adherence to the same study treatment.

  • Patients with minimum education: five years (elementary school).

    • Patients who present rates below those expected for their age group in at least 3 of the executive functions assessed on neuropsychological tests, and evaluation of executive functions.
  • Patients with stable clozapine and which have not been recently admitted (3 months).

Exclusion Criteria
  • Comorbid diagnosis of substance dependence or other psychiatric Axis I;
  • History of head trauma and / or other neurological problems;
  • Medical problems that compromise somehow the central nervous system;
  • History of mental retardation;
  • Patients treated with medication other than clozapine;
  • Patients who are suffering other psychosocial treatments.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
BADS (Behavioral Assessment of Functional Status)up to 6 months follow-up.

It is a battery which measures neuropsychological executive functions.

Secondary Outcome Measures
NameTimeMethod
DAFS-BR ( Direct Assessment of Functional Status), ILSS-BR (Habilities of Daily Living-Brazilian validated version).at baseline, after 30 sessions of treatment and follow-up 6 months.

DAFS-BR - Evaluates functional aspects of daily living such as dealing with money, shopping, social comunication ILSS-BR- similar to DAFS.

Trail Making A/B, Digit Span, Wisconsin Card Sorting Test, Stroop Color Test, Rey Complex Figure, Verbal Fluency,Tapping Visual and Logical Memory.at baseline, after 30 sessions of treatment and 6 months follo-up.

Neuropsychological Battery (Trail Making A/B, Digit Span, Wisconsin Card Sorting Test, Stroop Color Test,Rey Complex Figure, Verbal Fluency, Tapping Visual and Memória Logica)which measure cognitive functions.

Trial Locations

Locations (1)

Instituto de Psiquiatria do HCFMUSP

🇧🇷

São Paulo, Brazil

Instituto de Psiquiatria do HCFMUSP
🇧🇷São Paulo, Brazil
Adriana Vizzotto, BSc
Contact
+55 11 26618043
adrivizzotto@usp.br
Helio Elkis, MD PhD
Contact
helkis@usp.br
Helio Elkis, PhD MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.